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Abstract
Acute fever is one of the most common presenting symptoms globally. In order to reduce
the empiric use of antimicrobial drugs and improve outcomes, it is essential to improve diag-
nostic capabilities. In the absence of microbiology facilities in low-income settings, an assay
to distinguish bacterial from non-bacterial causes would be a critical first step. To ensure
that patient and market needs are met, the requirements of such a test should be specified
in a target product profile (TPP). To identify minimal/optimal characteristics for a bacterial
vs. non-bacterial fever test, experts from academia and international organizations with
expertise in infectious diseases, diagnostic test development, laboratory medicine, global
health, and health economics were convened. Proposed TPPs were reviewed by this work-
ing group, and consensus characteristics were defined. The working group defined non-
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severely ill, non-malaria infected children as the target population for the desired assay. To
provide access to the most patients, the test should be deployable to community health cen-
ters and informal health settings, and staff should require <2 days of training to perform the
assay. Further, given that the aim is to reduce inappropriate antimicrobial use as well as to
deliver appropriate treatment for patients with bacterial infections, the group agreed on mini-
mal diagnostic performance requirements of >90% and >80% for sensitivity and specificity,
respectively. Other key characteristics, to account for the challenging environment at which
the test is targeted, included: i) time-to-result <10 min (but maximally <2 hrs); ii) storage con-
ditions at 0–40°C,90% non-condensing humidity with a minimal shelf life of 12 months; iii)
operational conditions of 5–40°C,90% non-condensing humidity; and iv) minimal sample
collection needs (50–100μL, capillary blood). This expert approach to define assay require-
ments for a bacterial vs. non-bacterial assay should guide product development, and enable
targeted and timely efforts by industry partners and academic institutions.
Background
Acute fever is one of the most common presenting symptoms in healthcare facilities in resource
limited countries, and acute febrile illness (AFI) results in considerable morbidity and mortality
annually [1–3]. Until recently, malaria was considered to be the predominant cause of fever in
many endemic regions of the world. However, with the increased use of malaria rapid diagnostic
tests (RDTs), it has become apparent that a much smaller proportion of fevers are in fact caused
by malaria parasites than previously understood [4]. Recent global studies of fever etiology have
highlighted a great diversity of causative pathogens that vary depending study population, with
considerable variability in prevalence and diversity both within and between countries [5–11].
The decreased incidence of malaria, a paucity of even rudimentary microbiology facilities
due to a lack of human and financial resources, missing rapid diagnostic assays and the absence
of reliable clinical signs and symptoms has led to an increased uncertainty of algorithm-driven
empiric use of antimicrobials [11]. The overuse of antimicrobial drugs contributes to the global
increase of antimicrobial resistance (AMR) and it is estimated that currently 500,000 people
die annually from infections caused by drug resistant pathogens [12,13]. In low and middle
income countries (LMICs), antimicrobial overuse is probably greater, given the paucity of diag-
nostic tests, fewer controls on antimicrobial dispensing, and a lack of antimicrobial stewardship
programs [2,11,14] which likely contributes to an antibiotic resistance problem of alarming
magnitude [15,16]. The importance of diagnostic tests for evidence-based treatment has been
recognized by the World Health Organization (WHO) and other global health stakeholders as
a direct means of reducing the inappropriate use of antimicrobials and decreasing selective
pressure on microbes toward drug resistance [17]. Further an executive order on AMR pub-
lished by the president of the United States highlights the need for multidisciplinary
approaches including the development of point of care diagnostic [18].
In addition to limiting inappropriate antibiotic use, targeted and evidence-based treatment
will improve patient outcomes, reduce adverse events, and provide economic benefit for the
healthcare system and the patient [19]. Excessive health care spending is of particular concern
in many LMICs, where health care spending is primarily out-of-pocket expenditure [20]. A
number of studies have highlighted the lack of available assays to fill this diagnostic gap in
resource-limited settings [13,18–20]. Assays for detecting host biomarkers associated with bac-
terial fevers, such as C-reactive protein (CRP) and procalcitonin (PCT) are used in hospitals in
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Europe to differentiate between bacterial and non-bacterial infections [21], and guide triage
and treatment decisions [22–24]. However, malaria, co-infections such as HIV, and the pres-
ence of poverty-related diseases and conditions such as malnutrition have been shown to con-
found the interpretation of CRP and PCT results, limiting the value of these assays in LMICs
[25–29]. Thus, while the use of existing CRP or PCT tests could, in some settings, cost-effec-
tively improve the management of fever when compared with current practice [2,30], there is
likely to be considerable further advantage in improved biomarker tests that will be applicable
to a wider range of patients, once available. In recent years a number of promising assays have
been described in the literature that use single or combinations of biomarkers to predict bacte-
rial versus non-bacterial causes of fever. These assays, recently described in a systematic review,
might represent encouraging alternatives to CRP or PCT assays [31].
As novel platforms and technologies for biomarker detection and pathogen-specific testing
are being developed in the near term (5-years), it is important to ensure they meet the needs of
end-users. In particular, it is essential that the technological challenges faced at lower levels of
the health care system in resource-limited settings are taken into consideration during the
product development process [32].
Here, we describe the TPP definition process, involving a consortium of global health and
diagnostic experts, and the final consensus characteristics for a test to distinguish bacterial
from non-bacterial infections. The core group included individuals from the World Health
Organization (WHO), ReAct–Action on Antibiotic Resistance, Médecins sans Frontières
(MSF) Access Campaign and the Foundation for Innovative New Diagnostics (FIND). These
organizations convened a fever biomarker diagnostics meeting in September 2015 [33], and
established a TPP working group to develop the product specifications described here.
Methodology
Following a review of the current biomarker landscape [31] the need for TPPs was identified.
Preparing the presented TPPs for an assay to differentiate between bacterial and non-bacterial
infections was a collective effort initiated prior to the biomarker meeting in September 2015
(Geneva, Switzerland) [33]. An adapted Delphi approach with three rounds of input was used
to obtain an expert driven consensus for TPPs. In preparation for the meeting a first draft of
TPP characteristics was shared among the convening organizations (S1 File). Assay and plat-
form characteristics outlined in the TPPs had previously been agreed upon by experts and as
the listed characteristics were considered of being of the highest importance to guide product
development in compliance with ISO13485 and 21CFR Part 820. The listed characteristics are
therefore used in all FIND TPPs (http://www.finddx.org/target-product-profiles/). TPP charac-
teristics are described as either “acceptable” or “desired.” An assay’s attributes or characteristics
are defined as “acceptable” when they are considered minimum criteria and thresholds that
must be reached in order for the diagnostic tool to be useful to health care providers and bene-
ficial for patients in the defined site of use. “Desired” characteristics refer to optimal attributes
or characteristics that are highly desirable by healthcare workers and patients.
The first draft was based on a review of relevant literature related to the selected characteris-
tics (S2 File). Prior and during the biomarker meeting, recognized leaders in the field were
identified for the final TPP working group (n = 15) based on their proven expertise in the field
of non-malarial fever and/or biomarker studies in resource limited settings. The group was
composed of experts in infectious disease, laboratory medicine, microbiology, global health,
health economists, and diagnostic test development. To reduce the bias introduced by the
expert driven approach, stakeholders working in a wide range of geographical regions and
backgrounds were chosen. Based on the feedback in the first round a second TPP draft was
TPPs for a Biomarker Test to Guide Antibiotic Treatment
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prepared and circulated among the participants of the working group with the request for critical
input (S3 File). Feedback and discussion points obtained in this second round of review were
compiled in advance of a face-to-face consensus meeting (S4 File). Based on the feedback, attri-
butes and characteristics were revised by FIND and prioritized for further discussion based on
the level of concordance/discordance in the responses (Table 1). The draft characteristics were
then presented by FIND to the meeting participants and discussed during a workshop held in
Geneva in February 2016 which was attended in person or via conference link by 13 participants.
If personal attendance was not possible the final TPP as well as discussion points were shared
with active members (n = 14) of the initial TPP working group. All dissent and discussion points
raised during the meeting were noted, and a concerted effort was made to reach full agreement.
Final consensus TPPs were established after unanimous agreement by the group.
Results
Scope of the test
The working group identified an assay to distinguish bacterial from non-bacterial infections as
a top priority to improve fever management in low-resource settings [33]. The aim of such a
test would be to rule in or rule out bacterial infections and therefore provide actionable, evi-
dence-based treatment guidance. The acceptable population such a test should be focused on
non-malarial acute pediatric febrile illness patients (2month– 12years) without severe disease
(Table 2), as defined by WHO guidelines like the IMCI [34]. This was identified as the priority
age group in order to reduce undifferentiated use of antimicrobials given the large incidence of
febrile episodes in this population and the higher morbidity and mortality in children com-
pared to older children and adults [35]. Ideally (“desired”) however, the target age range of a
new assay should include all ages, including neonates. While in the “acceptable” the population
is restricted to non-malarial patients the desired assay could also be performed without the
inclusion of a downstream malaria test on the total febrile population. Primary health care
facilities (level 1) and informal health care settings (level 0) with untrained or minimally
Table 1. Target product profile characteristics and their priority, expert consensus process 2015–16.
Priority for
discussion
Characteristics
High Target population, Level of health system, Analytical sensitivity/Limit of Detection
(LOD), Diagnostic sensitivity/speciﬁcity, Target price, Time-to-result, Hands-on-time,
Training requirements
Medium Multiplexing, Ease of test performance, Sample type, Additional sample preparation,
Throughput, Result stability, Shipping conditions, Equipment, Calibration,
Connectivity, Reproducibility
Low Target user, Volume, Reagent preparation, Waste disposal, Power supply, External
maintenance, Data interpretation
Very low Sample collection, Kit conﬁguration, Control material, Analysis type, Biosafety,
Storage conditions, Operation conditions, Water supply
A total of 35 test characteristics were included in the TPP, as shown in the list below. The following deﬁnitions
were used for ranking. High: Large divergence between expert opinions, and/or signiﬁcant implications for
the ﬁnal assay, and/or limited published evidence to guide decision. Medium: Some divergence between
expert opinions, and/or Limited published evidence to guide decision, and/or review of wording after
changes, and/or common characteristics modiﬁed after initial review. Low: Some divergence between expert
opinions, and/or limited implications for the ﬁnal assay, and/or strong published evidence available to guide
decision. Very low: No divergence between expert opinion, and/or FDA/industry consensus already
available.
doi:10.1371/journal.pone.0161721.t001
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trained staff represent the most diagnostically underserved facilities in many health care sys-
tems, particularly in resource-limited settings and were therefore identified as the target setting
for this assay (Table 2). Based on a 2006 review by Lim et al., an assay implemented at these
levels will impact the largest number of febrile patients [36]. The TPPWorking Group agreed
that a test with high sensitivity is important to improve treatment outcomes through early
detection of patients in need of treatment.
Further to reduce antibiotic overuse confidence in test ability to detect bacterial infection is
needed (high sensitivity). This needs to be combined with decent specificity to limit false posi-
tive result. The working group agreed that a specificity of80% would be a strong improve-
ment on the current situation, where empiric antibiotic use is the norm. A recent study from
South East Asia demonstrated that 38% of all febrile patients received an antimicrobial and
that this was not focused on bacterial infections alone [2]. In Africa, the overuse of antibiotics
seems to be even larger, with between 50% and 80% of febrile outpatients receiving antibiotics
[39].Test price estimates are based on expert opinion, and estimates of what is acceptable (<5
USD) or desirable (<1 USD) out-of-pocket costs in LMICs. As with other RDTs (e.g., for HIV
or malaria), it is expected that prices would decline over time as market demand increases,
costs of production reduce due to volume-based efficiencies of scale, and competition increases
due to multiple suppliers [40].
Test and operational characteristics
The group agreed that, in the absence of pathogen-specific tests, at a minimum a new fever
assay needs to be able to distinguish between bacterial and non-bacterial infections, after
malaria has been ruled out. However, an additional strength would be the inclusion of addi-
tional analytes, particularly a pathogen-specific marker for the detection of malaria. In some
settings, other geographically relevant pathogens (e.g., Dengue, O. tsutsugamushi [2]) as well as
markers of disease severity would be “desired” features (Table 3).
Table 2. Acceptable and desired target product profile characteristics focused on the scope of the test, as defined by an expert consensus pro-
cess 2015–16.
Characteristic Acceptable ("must have") Desired ("would like") Reference
Goal Rapid, biomarker-based testing to differentiate between bacterial and non-bacterial
infections to guide antimicrobial treatment.a
Expert
consensus
Target population Children with non-severe, non-malarial acute
fever presenting at health facilities. b,c,d
Total febrile population (including
neonates) presenting with fever. b,c,d
[4,35]
Target level of health system Level 1, passive case ﬁnding Level 0 [37]
Target user Healthcare worker Trained lay person [38]
Price of individual test (Ex works) 5 USD e <1 USD e Expert
consensus
Analytical sensitivity/Limit of detection Limit of detection should be such that it allows clinically relevant performance as
deﬁned below
Expert
consensus
Diagnostic sensitivity to differentiate between
bacterial and non-bacterial infections
90% 95% Expert
consensus
Diagnostic speciﬁcity to differentiate between
bacterial and non-bacterial infections
80% 90% Expert
consensus
a Biomarker: nucleic acid, proteins or any other analytes that is found to be able to differentiate between bacterial and non-bacterial infections
b Non-severe: deﬁnition according to IMCI guidelines[34]
c Acute fever: less than 14 days
d Fever: >37.5°C at presentation or within last 48h
e Ex works as deﬁned by Incoterms 2010 standards
doi:10.1371/journal.pone.0161721.t002
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Table 3. Acceptable and desired target product profile characteristics focused on operational characteristics, as defined by an expert consensus
process 2015–16.
Characteristic Acceptable ("must have") Desired ("would like") Reference
Multiplexing 1 analyte 1 analyte plus pathogen speciﬁc
testing (priority: malaria)
Expert consensus
Ease of test performance 2 timed steps during assay performance No timed step during the assay
performance
Expert consensus
Sample type Capillary blood or urine Capillary blood or any less invasive
sample than blood, like: Saliva
Expert consensus
Volume - Capillary blood:
- patients > 6 years[41] - 100μL (~ 4 drops);
- pediatric patients 2–6 years[41]– 50–100μL (~2
drops);
- Saliva: < 0.5mL
- Urine: ~1mL of urine
- Capillary blood: 25μL (~1 drop) for
all age groups
- Saliva: <0.5mL for saliva
Expert consensus
Sample collection Transfer and quantiﬁcation device included in the test Industry standard
Additional sample
preparation
1 sample-processing steps None required Expert consensus
Kit conﬁguration No additional reagents outside of the kit required (including gloves) Industry standard
Process control Internal control to provide test validity and acceptance Expert consensus
Batch/Quality control Positive and negative controls required to monitor the quality of kit Expert consensus
Reagent preparation - Minimal of one additional step to prepare prior to use
- No (precise) measuring required.
No additional reagents required,
everything is provided ready-to-use
[32]
Time to result (per
sample)
<2 hours <10min Expert consensus, Ivanova
et. al. in preparation
Hands on time Total hands-on-time should be <5 min Total hands on time should be <1 min Expert consensus
Sample throughput Ability to test individual samples or multiple samples if needed (no need for batching) Expert consensus
Result stability 15 min 1 hour Industry standard
Assay type Qualitative Quantitative Expert consensus
Biosafety No need for a biosafety cabinet; basic safety procedures need to be followed [42]
Waste disposal Biohazard waste - Testing device
- Compostable plastics for minimal
environmental impact
[42]
Storage conditions and
Self-life
- 12 month at ﬂuctuating temperature (0–40°C)
-90% relative humidity
- No controlled temperature required
- 24 month at ﬂuctuating temperature
(0–50°C)
-90% relative humidity
- No controlled temperature required
Expert consensus
Operation conditions - Between 5°C—40°C
-90% humidity
- Between 5°C—45°C
-90% humidity
Expert consensus
Shipping conditions Shipping without cold chain; should tolerate stress during transport (72h at +50°C) Expert consensus
Training requirementsa <2 days including proﬁciency panel <0.5 day including proﬁciency panel [32]
Equipment (instrument
external to test)
Small, robust, dust-resistant, portable or hand-held
integrated instrument that must operate on battery
Reusable instrumentation not required Expert consensus
Power supply Battery or solar powered None required [32]
Water supply No external water required Industry standard
External maintenance - Preventative maintenance at 2 year or >4000
samples; simple with only minimal expertise
- Maintenance alert should be included.
None required Industry standard
Calibration Remote calibration or auto-calibration No calibration required Industry standard
Data output Qualitative Non-ambiguous results displayed
(e.g. bacterial/non-bacterial–yes or
no)
Expert consensus
Data interpretationb Minimal interpretation required No interpretation required Expert consensus
Connectivity Not required Wireless connectivity Isaak et. al. in preparation
(Continued)
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Capillary blood, saliva and urine were considered “acceptable” sample matrices (Table 3).
Experts note that while for adult patients urine is an accessible and ideal non-invasive clinical
sample, in small children obtaining urine can be difficult and time-intensive; with one study
reporting a median of 25 minutes to obtain urine from children using either pads, bags, or
clean catch methods [44]. Thus, urine does not represent an ideal sample for point-of-care test-
ing in our target setting, given the importance of a test appropriate to children. Similarly,
obtaining venous blood from infants and small children can be challenging; the TPPWorking
Group agreed that blood volumes should be restricted to ~50–100μL (~2 drops) or ~100 μL
(~4 drops) for children or adults, respectively (Table 3).
Time-to-result is defined as the time between sample collection and reporting the result. It
was agreed that the ideal test should be used within the time constraint of a patient consulta-
tion, while the maximum “acceptable” time to result would be two hours (Table 3). The latter
estimate is based on clinical experience with the amount of time patients are willing to wait,
particularly in rural health centers with large catchment areas that require patients to travel
long distances.
Depending on the catchment area, season, and geographical location, the number of
patients presenting at health facilities can fluctuate and health providers need to be able to per-
form one or many tests simultaneously, comparable to the current malaria RDTs. Hence, a
hands-on time of<5 minutes was defined as acceptable and under one minute as desirable.
The TPPWorking Group agreed that, based on the target setting and user of this test, training
requirements should be minimal, and enable proficiency of the end user (with limited biomedi-
cal training) after a maximum of two training days (Table 3). Further, the group also identified
connectivity as a “desired” characteristic. This is particularly the case as new barcoding and
connectivity technologies allow for improved records including data on test type, lot numbers,
manufacturing dates and expiry dates. Connectivity options can also allow for closer integra-
tion of the test with electronic patient management algorithms that have been shown to
improve antibiotic targeting [45].
Discussion
Establishing and disseminating the TPPs of diagnostic tests identified as high priority will help
guide product development teams. In the case of AFIs, this would be expected to accelerate the
development of much needed tools. In addition, by making the approach and analysis trans-
parent, and distinguishing areas of broad expert agreement as well as divergence, groups
involved in diagnostic test development can make informed decisions about product features
and performance specifications.
Accurate diagnosis of febrile illness is critical for appropriate, individualized patient care
and improved public health, as “without diagnostics, medicine is blind” [46]. Unfortunately,
the wide range of causative agents of fever, and in many cases non-specific clinical features of
diverse infections make pathogen-specific diagnoses challenging. While the challenges associ-
ated with identifying causative agents of fever are universal, the lack of human, financial and
Table 3. (Continued)
Characteristic Acceptable ("must have") Desired ("would like") Reference
Reproducibility >95% standard deviation between repeats [43]
a Training to use the test, not including clinical/treatment implications and consequences.
b Interpretation of the test result, not the clinical/treatment conseque
doi:10.1371/journal.pone.0161721.t003
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structural capacity significantly complicates patient care in LMICs. This is particularly true for
level 1 and level 0 where, as described by Lim and colleagues, the largest proportion of patients
in Africa, Asia, and Latin America access care [36]. Therefore, diagnostic tests at these levels
need to fulfill the WHO proposed Affordable Sensitive Specific User-friendly Rapid and Equip-
ment-Delivered (ASSURED) criteria [38,47].
As a first step to address the need to provide adequate treatment to many millions of
patients, the TPP presented here has been established to guide the development of new diag-
nostic assays, or the adaptation of available assays. The diagnostic characteristics described can
be viewed as guides to product development; the final performance characteristics, including
clinical sensitivity and specificity, would need refinement based on population needs and mar-
ket dynamics. However, while the current group slightly favored sensitivity over specificity in
this performance trade-off, the defined diagnostic parameters (sensitivity/specificity) are in
line with previous estimates for acute lower respiratory infection (ALRI) [36]. The 2006 study
by Lim and colleagues concluded that a similar test, targeted only at ALRI, with 95% sensitivity
and 85% specificity would save ~ 405,000 children annually [36]. An additional challenge is the
lack of reference standards and curated specimen banks for bacterial and non-bacterial infec-
tions against which biomarker tests can be evaluated. The desired use of a multiplexed or
multi-analyte approach could further help to conserve human and economic resources. In
most instances, however, given its prevalence, global burden of disease, public health impor-
tance, and curative treatment regimens, a biomarker plus malaria combi-test should be priori-
tized. Market analyses remain to be conducted to understand what the sustained demand for
such tests would be, based on geography and health system. Defining a target price for the
assay is also a complex challenge as the market for such an assay is not well defined in LMICs.
For the purposes of this TPP, we assumed that price pressures will be similar to those observed
in the current RDT market for malaria [40].
Although product developers should aim to meet the defined characteristics as closely as
possible, given the paucity of available assays, some flexibility in the specifications is appropri-
ate. Some of the “acceptable” criteria were chosen deliberately general and matching those
might result in reduced uptake of an assay. We acknowledge that depending on the technical
approach taken by developers, the small sample volumes proposed by us can pose a challenge
for pathogen-specific tests with low magnitude bacteremia or antigenemia [48]. Another limi-
tation of the presented TPP is the extent to which it had to rely on expert opinion as specific
studies around health seeking behavior were not available due to the lack of published targeted
investigations. This lack of information identified by our group should encourage targeted
investigations into the health care seeking behavior as well as socio-economic barriers associ-
ated with fever diagnostic. The inclusion of stakeholders from diverse backgrounds, with a
wide range of experiences in different countries and settings, aimed to counteract the bias
potentially introduced by this expert-based approach. A further limitation might be the exclu-
sion of industry stakeholders a decision taken to allow the development of TPPs that exclu-
sively focused on patient health care provider’s needs.
The availability of fever biomarker assays, even with excellent performance characteristics,
is unlikely to have sustained impact unless endorsed and incorporated into corresponding
WHO treatment guidelines, similar to the P. falciparum rapid tests [34]. For example, integrat-
ing a biomarker test within the Integrated Management of Childhood Illness (IMCI; WHO) or
Integrated Management of Integrated Management of Adolescent and Adult Illness (IMAI;
WHO) [34,49] would add more classifications to the existing decision algorithm, and would
therefore help health care providers make informed treatment decisions [7,19,29,50]. Currently
health care providers are advised to administer antimicrobials to patient with “an identified
bacterial cause of fever” [34], which relies on the subjective assessment of the clinician without
TPPs for a Biomarker Test to Guide Antibiotic Treatment
PLOS ONE | DOI:10.1371/journal.pone.0161721 August 25, 2016 8 / 12
any diagnostic guidance. The addition of a specific assay, meeting the TPP specifications
described here, would further allow the classification of patients as either “requiring” or “not
requiring” antibiotics and reduce the excessive use of antibiotics.
In summary, the described TPP will guide the development of innovative diagnostic plat-
forms that can help to distinguish between bacterial and non-bacterial infections, and guide
individualized treatment decisions in LMICs. Although development of a suitable test is the
first step, the working group is aware that large scale clinical trials with different populations
and pre-test probability of bacterial infection are necessary to understand the final diagnostic
performance in the target settings. However, with more than 90 million patients presenting to
African health facilities with non-malarial fevers every year [4] the global health need is large
and implementation of a tool could have large impact. The experts convened for this project
agreed with previous analyses that a validated bacterial vs. non-bacterial assay is just the begin-
ning, and TPPs for simple, rapid, pathogen-specific assays, especially for pathogens requiring
specific antimicrobial choices (e.g., Gram-positive infections, pathogens resistant to standard
therapy, tetracycline-responsive pathogens) as well as triage tests (e.g. need for referral of sever
viral and/or bacterial infections) are also needed [19,50,51].
In line with Derda and colleagues we would like to reiterate the call for cross-continental
collaborations and encourage all stakeholders (industry, academia, non-for-profit, non-govern-
mental-organizations) to initiate collaborations early in the developmental, evaluation and val-
idation process to allow for successful and timely technology advances of assays needed to save
lives and reduce the threat of antimicrobial resistance [52].
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